Analytical Data
-
Gene name
CUTA
- Application
-
Alternative Names
CUTA；ACHAP；C6orf82；;Protein CutA
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
O60888
-
Expression Region
33-179aa
-
AA Sequence
RLLLLPRV LLTMASGSPP TQPSPASDSG SGYVPGSVSA AFVTCPNEKV AKEIARAVVE KRLAACVNLI PQITSIYEWK GKIEEDSEVL MMIKTQSSLV PALTDFVRSV HPYEVAEVIA LPVEQGNFPY LQWVRQVTES VSDSITVLP
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
CUTA, or CXC-chemokine receptor type 4 (CXCR4) and UPF1 associated protein, is a crucial player in various cellular processes, including immune response and cell signaling. The research surrounding CUTA recombinant proteins has gained momentum due to their potential therapeutic applications, particularly in cancer treatment and regenerative medicine. CUTA’s involvement in the CXCR4 signaling pathway makes it a target for interventions that aim to modulate immune responses or inhibit tumor growth, given that CXCR4 is often overexpressed in various cancers, facilitating metastasis and poor patient prognosis. Additionally, the study of CUTA recombinant proteins contributes to understanding the underlying molecular mechanisms of autoimmune disorders and infectious diseases, where the regulation of chemokine signaling is pivotal. Advances in recombinant DNA technology have enabled the production of CUTA in sufficient quantities for detailed biochemical and functional studies, which are essential for exploring its interactions with other proteins and its role in cellular pathways. Furthermore, the characterization of CUTA recombinant proteins may pave the way for the development of novel therapeutics that specifically target the CXCR4 pathway in clinical settings, thereby enhancing treatment efficacy and patient outcomes. The ongoing research seeks to elucidate the full spectrum of CUTA's biological functions and its potential as a biomarker or therapeutic target in various diseases, underscoring the importance of this protein in both basic and applied biomedical research.
